Navigation Links
CV Therapeutics Announces License Agreement for Ranexa(R) in Europe With Menarini Group
Date:9/12/2008

y dialing (706) 645-9291; the PIN access number is 64328875.

About Angina

There are currently 48-50 million angina prescriptions written annually in the largest five EU member countries (UK, Germany, France, Spain and Italy). Chronic angina is a serious and debilitating heart condition, usually associated with coronary artery disease and marked by repeated and sometimes unpredictable attacks of chest pain.

About Menarini

The Menarini Group is one of the largest privately owned pharmaceutical companies, and is headquartered in Florence, Italy. Menarini employs approximately 12,500 people, with a strong presence throughout Europe, CIS, Africa and in South and Central America. The company has expertise in successfully developing and commercializing in-licensed drug products from major companies in a broad range of therapeutic areas. The Group's total revenue exceeds euro 2.5 billion.

About CV Therapeutics

CV Therapeutics, Inc., headquartered in Palo Alto, California, is a biopharmaceutical company primarily focused on applying molecular cardiology to the discovery, development and commercialization of novel, small molecule drugs for the treatment of cardiovascular diseases. CV Therapeutics Ltd. is the company's European subsidiary based in the United Kingdom.

CV Therapeutics' approved products in the United States include Ranexa(R) (ranolazine extended-release tablets), indicated for the treatment of chronic angina in patients who have not achieved an adequate response with other antianginal drugs, and Lexiscan(TM) (regadenoson) injection for use as a pharmacologic stress agent in radionuclide myocardial perfusion imaging in patients unable to undergo adequate exercise stress.

Except for the historical information contained herein, the matters set forth in this press release, including statements as to research and development and commercialization of products, are forward-looking statements within the meaning of
'/>"/>

SOURCE CV Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

1

GOOD

Page: 1 2 3 4 5

Related biology technology :

1. Cell Therapeutics to Host Investor Day in Milan, Italy on Friday, October 3, 2008
2. Halozyme Therapeutics to Present at Upcoming Investor Conferences
3. Intarcia Therapeutics, Inc. Announces Appointment of Kenneth Luskey, M.D. as Vice President, Clinical Research
4. Halozyme Therapeutics Strengthens Management Team, Appoints Additional Experienced Executives
5. CV Therapeutics Initiates Phase 1 Clinical Trial of CVT-3619, a Novel Potential Treatment for Cardiometabolic Diseases
6. Amicus Therapeutics to Present at the 2008 BioCentury NewsMakers in the Biotech Industry Conference
7. Orexigen(R) Therapeutics to Present at Upcoming Investor Conferences
8. CV Therapeutics Reports Option Grants Under Nasdaq Marketplace Rule 4350
9. Nile Therapeutics to Present at BioCenturys NewsMakers in the Biotech Industry Conference
10. TorreyPines Therapeutics Receives NASDAQ Deficiency Notice
11. Cell Therapeutics, Inc. Announces Reverse Stock Split
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/18/2013)... June 18, 2013 Earlier this year, Google ... platform. As this directly impacts the core component of ... one of the most sweeping updates since its inception in ... Technologies recently posted a very informative article on ... ‘must-have’ upgrade date for enhanced campaigns . Only ...
(Date:6/18/2013)... DC (PRWEB) June 18, 2013 On ... Services (CMS) released a final decision memorandum concluding ... to guide subsequent management of anti-tumor strategy, and ... collection. The National Oncological PET Registry (NOPR) was developed ... the first projects under the Coverage with Evidence Development ...
(Date:6/18/2013)... NY (PRWEB) June 18, 2013 ... software, today announces a new Fast-Track award from the ... integrated design-analysis environment (IDAE) for the nuclear power industry. ... halted for more than 30 years, but the United ... to remarkable gains in power plant utilization through improved ...
(Date:6/17/2013)... 2013  KaloBios Pharmaceuticals, Inc. (Nasdaq: KBIO ... Joseph as Chief Legal Officer.  Mr. Joseph brings ... and has worked in both public and private companies, ... (Logo: http://photos.prnewswire.com/prnh/20130225/MM66380LOGO ) "Don ... general counsel and senior executive and his knowledge and ...
Breaking Biology Technology:Core and More Technologies Helps Organizations Migrate to Google’s Enhanced Campaign Structure 2Core and More Technologies Helps Organizations Migrate to Google’s Enhanced Campaign Structure 3WMIS Welcomes CMS Decision: Expanding Coverage for FDG-PET and Ending NOPR Data 2WMIS Welcomes CMS Decision: Expanding Coverage for FDG-PET and Ending NOPR Data 3Kitware to Develop an Open-Source HPC Design-Analysis Environment for Nuclear Energy Research 2KaloBios Appoints Donald R. Joseph as Chief Legal Officer 2KaloBios Appoints Donald R. Joseph as Chief Legal Officer 3KaloBios Appoints Donald R. Joseph as Chief Legal Officer 4
... - Exploiting a novel technique called phase discontinuity, researchers at ... induced light rays to behave in a way that defies ... published this week in Science , has led to ... of a ray of light bouncing off a surface or ...
... /PRNewswire-iReach/ -- Advanced Technological Education Television (ATETV), an ... National Science Foundation , returns with 40 new videos just ... is a free Web video series featuring up to the ... and employment opportunities. The series debuted in 2009 and has ...
... 2011 An online library of cellular images freely ... celebrated its one-year anniversary on August 9, 2011 by ... favorite website. The Scientist announced the readers, ... from the judges. The Cell has more than 3,000 ...
Cached Biology Technology:From a flat mirror, designer light 2From a flat mirror, designer light 3New Videos Spotlight Science/Technology Careers and Educational Path To Secure Jobs in Them 2Free Online Library of Cell Images Wins 'The Labby' 2
(Date:6/18/2013)... Medicine have discovered a mechanism that is used to ... of blood typically associated with clotting, were discovered to ... it off from the rest of the body. The ... this week, provide the science community with a greater ... that platelets do participate in immunity, but now it,s ...
(Date:6/18/2013)... the Energy Department,s National Renewable Energy Laboratory (NREL), ... a paper describing a novel cellulose-degrading enzyme from ... commonly known as the gribble. , Gribbles ... unique ability to produce their own enzymes instead ... biomass they eat. New biomass-degrading enzymes from novel ...
(Date:6/18/2013)... environmental engineer has been awarded a $394,300 grant ... water quality and flow in the new facilities ... Kruzic, UT Arlington associate professor of civil engineering, ... add monochloramine to the water in an effort ... stations and pipelines. Adding monochloramine is widely practiced ...
Breaking Biology News(10 mins):Immunity mechanism discovered 2Novel enzyme from tiny gribble could prove a boon for biofuels research 2UT Arlington research to benefit quality, flow in 150-mile Integrated Pipeline 2
... or community taken to combat childhood obesity? The percentage ... 35 years. Local governments play a crucial role by shaping ... to find fresh fruits and vegetables, play outdoors, walk, and ... TO PREVENT CHILDHOOD OBESITY, a new report from the Institute ...
... air cargo scanning technology team has been awarded ... Prize for Outstanding Science in Support of Defence ... outstanding science and/or technology with the potential to ... security. Security and border protection are key ...
... Blacksburg, Va. -- After engineers and scientists at Virginia Tech, ... water, Michael Phelps may find he still has a few ... ,The remarkable ability of fish to maneuver in ... to accelerate in a seemingly effortless fashion has researchers wondering ...
Cached Biology News:Tackling childhood obesity at the local level -- IOM report releases Sept. 1 2NSF Emerging Frontiers' program supports development of smart materials based on study of fish 2NSF Emerging Frontiers' program supports development of smart materials based on study of fish 3
Human Xg Affinity Purified Polyclonal Ab Keywords: Xg glycoprotein, hereditary hemorrhagic telangiectasia Protein Family: ...
in vitro Translation, Accessory Products...
...
Mouse Collagen IV...
Biology Products: